Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT07403812

Assessing DCog Short for Neurotoxicity in CAR-T

Conditions: Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: NA

Enrollment: 40

Sponsor: Beth Israel Deaconess Medical Center

Location: Beth Israel Deaconess Medical Center Boston Massachusetts

Summary

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Eligibility Criteria

Inclusion Criteria: * participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity. * Visual acuity of 20/100 or better. Exclusion Criteria: * patients \< 18 years old * pregnant women * prisoners * adults unable to consent, * participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07403812). StuddyBuddy aggregates publicly available trial information.